[1]遆振宇a,高小鹏,千东维b,等.血清 sPDL1水平和外周血 NLR在判断晚期胆管癌患者生存预后中的意义[J].现代检验医学杂志,2019,34(06):41-46.[doi:10.3969 / j.issn.1671-7414.2019.06.010]
 TI Zhen-yua,GAO Xiao-peng,QIAN Dong-wei,et al.Soluble Programmed Death-Ligand 1 (sPDL1) and Neutrophilto-Lymphocyte Ratio (NLR) Predicts Prognostic Survival in Advanced Biliary Tract Cancer Patients Treated with Palliative Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(06):41-46.[doi:10.3969 / j.issn.1671-7414.2019.06.010]
点击复制

血清 sPDL1水平和外周血 NLR在判断晚期胆管癌患者生存预后中的意义()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第34卷
期数:
2019年06期
页码:
41-46
栏目:
论著
出版日期:
2019-12-30

文章信息/Info

Title:
Soluble Programmed Death-Ligand 1 (sPDL1) and Neutrophilto-Lymphocyte Ratio (NLR) Predicts Prognostic Survival in Advanced Biliary Tract Cancer Patients Treated with Palliative Chemotherapy
文章编号:
1671-7414(2019)06-041-06
作者:
遆振宇1a高小鹏2千东维1b慕喜喜2
(1. 西安市第三医院a. 普外二科;b. 手术室,西安 710018;2. 西安市中心医院普外二科 西安 710003)
Author(s):
TI Zhen-yu1a GAO Xiao-peng2 QIAN Dong-wei3 MU Xi-xi2
(1a. the Second Department of General Surgery; 2b. Operating Room, the Third Hospital of Xi’an, Xi’an 710018, China; 2. the Second Department of General Surgery, Xi’an Central Hospital,Xi’an 710003, China)
关键词:
可溶性细胞程序性死亡配体1胆管癌中性粒细胞与淋巴细胞比值总生存时数
分类号:
R735.8;R730.43
DOI:
10.3969 / j.issn.1671-7414.2019.06.010
文献标志码:
A
摘要:
目的 探究血清可溶性细胞程序性死亡配体1(soluble programmed death-ligand 1,sPDL1)水平和中性粒 与淋巴细胞比值(neutrophil-to-lymphocyte ratio,NLR)在晚期胆管癌(biliary tract cancer,BTC)患者中生存预后 的意义。方法 2017 年2 月~2019 年3 月收集西安市第三医院144 例晚期BTC 且进行姑息化疗的患者临床资料,包 括sPDL1 水平,NLR,血小板与淋巴细胞比值(platelet-tolymphocyte ratio,PLR)以及全身免疫炎症指数(systemic immune-inflammation index, SII)。采用单纯随机抽样方法验证每项标志物的分界值,将患者分为发展组与稳定组。比 较不同组患者的sPDL1 水平及总生存时间(overall survival,OS),分析影响患者生存预后的因素。结果 所有患者 OS 为9.12 个月(95% CI 8.24~11.41),sPDL1 中值为1.19(0.04~7.31)ng/ml,平均为1.45±1.18 ng/ml。NLR,PLR 及SII 的中位值分别为2.58,141.78 和583.95。高水平sPDL1(≥ 0.96 ng/ml)患者的OS 少于低水平sPDL1 患者, 差异具有统计学意义(P < 0.001)。高水平sPDL1(HR=2.048,95%CI=1.26~3.34,P =0.004)及NLR(HR=1.565, 95%CI=1.07~2.30,P =0.023)是患者预后较差的独立风险因素。结论 血清sPDL1 水平可以测定,且sPDL1 及NLR 在 晚期BTC 患者生存预后判断中具有重要临床意义。
Abstract:
Objective To explore the significance of serum soluble programmed death ligand 1 (sPDL1) level and peripheral blood neutrophil-to-lymphocyte ratio (NLR) in predicting survival and prognosis of patients with advanced biliary tract cancer (BTC). Methods From February 2017 to March 2019, the clinical data of 144 patients with advanced BTC undergoing palliative chemotherapy in the Third Hospital of Xi’an were collected, including serum sPDL1 level, NLR, platelet-to-lymphocyte ratio (PLR) and systemic immune inflammation index (SII). Simple random sampling was used to verify the demarcation value of each marker. The patients were divided into development group and stable group. The levels of sPDL1 and total survival time (OS) in different groups were compared, and the factors influencing the survival and prognosis of patients receiving palliative chemotherapy were analyzed. Results OS of all patients was 9.12 months (95% CI 8.24~11.41), median value of sPDL1 was 1.19(0.04~7.31) ng/ml , with an average of 1.45±1.18 ng/ml. The median values of NLR, PLR and SII were 2.58, 141.78 and 583.95, respectively. OS of patients with high level sPDL1 ( ≥ 0.96 ng/ml) was less than that of patients with low level sPDL1, the difference with statistical significance (P < 0.001). High levels of sPDL1 (HR=2.048, 95% CI=1.26~3.34, P =0.004) and NLR(HR=1.565, 95% CI=1.07~2.30, P =0.023) were independent risk factors for poor prognosis. Conclusion Serum sPDL1 level can be measured, and sPDL1 and NLR have important clinical significance in the prognosis of patients with advanced BTC.

参考文献/References:

[1] KOHLER B A, SHERMAN R L, HOWLADER N, et al. Annual report to the nation on the status of cancer, 1975-2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state[J]. Journal of the National Cancer Institute, 2015, 107(6): 36-38.
[2] 肖小平,郭 玲,张 熊. 胆管癌组织LOXL2 mRNA 与Tenascinm-C mRNA 表达的临床应用研究[J]. 现 代检验医学杂志, 2017, 32(3):79-81. XIAO Xiaoping, GUO Ling, ZHANG Xiong. Clinical application of the expression of LOXL2 mRNA and tenascin-C mRNA in tissues of the bile duct cancer[J], Journal of Modern Laboratory Medicine, 2017, 32(3):79-81.
[3] 周晓冬, 刘会利, 赵汉东, 等. 原发性胆汁性胆管炎 患者血清自身抗体及生化指标的特征分析[J]. 现代 检验医学杂志, 2016, 31(6):32-36. ZHOU Xiaodong, LIU Huili, ZHAO Handong, et al. Characteristic analysis of sera of autoantibodies and biochemical indexes of patients with primary biliary cholangitis[J], Journal of Modern Laboratory Medicine, 2016, 31(6):32-36.
[4] 侯建峰, 杨亚明, 王 莉, 等. 谷氨酸脱氢酶在肝外胆 管癌患者肿瘤组织中的表达及其临床意义[J]. 现代 检验医学杂志, 2018, 33(6):13-16,20. HOU Jianfeng, YANG Yaming, WANG Li, et al. Expression and clinical significance of glutamate dehydrogenase in tumor tissues of patients with extrahepatic cholangiocarcinoma[J], Journal of Modern Laboratory Medicine, 2018, 33(6):13-16,20.
[5] 李媛,胡正军. 髓源性抑制细胞- 免疫系统的调节成 分[J]. 现代检验医学杂志, 2011, 26(2):58-61. LI Yuan, HU Zhengjun. Myeloid-derived suppressor cells-regulatory components of the immune system[J]. Journal of Modern Laboratory Medicine, 2011, 26(2):58-61.
[6] KEISARI Y. Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation[J]. Frontiers in Bioscience, 2017, 22:310-347.
[7] MOHME M, RIETHDORF S, PANTEL K.et al. Circulating and disseminated tumour cells - mechanisms of immune surveillance and escape[J]. Nature Reviews Clinical Oncology, 2017, 14(3): 155-167.
[8] MARTIN O A, ANDERSON R L, NARAYAN K, et al. Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?[J]. Nature Reviews Clinical Oncology, 2017, 14(1): 32-44.
[9] 陈琬玲,朱旭,师娟, 等. 非小细胞肺癌肿瘤微环境 中IFN-γ,TGF-β, IDO 表达变化及其相关性[J]. 中 国肿瘤生物治疗杂志, 2016, 23(4): 510-514. CHEN Wanling, ZHU Xu, SHI Juan, et al. Expression changes of IFN-γ, TGF-β1 and IDO and their correlation in the tumor microenvironment of non-small cell lung cancer[J]. Chinese Journal of Cancer Biotherapy, 2016, 23(4): 510-514.
[10] SABATIER R, FINETTI P, MAMESSIER E, et al. Prognostic and predictive value of PDL1 expression in breast cancer [J]. Oncotarget, 2015, 6(7): 5449- 5464.
[11] WANG Yiwei, WANG Hang, ZHAO Qi, et al. PD-L1 induces epithelial-to-mesenchymal transition via activating SREBP-1c in renal cell carcinoma[J]. Medical Oncology, 2015, 32(8):212.
[12] GOLDFINGER M, XU Mina, BERTINO J R, et al. Checking in on lenalidomide in diffuse large B cell lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(6): e307- e311.
[13] WANG Liang, WANG Hua, CHEN Hao, et al. Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma [J]. Oncotarget, 2015, 6(38): 41228- 41236.
[14] HU Bo, YANG Xinrong, XU Yang, et al. Systemic immune- inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma [J]. Clinical Cancer Research, 2014, 20(23): 6212-6222.
[15] HANSEN M H, HURWIT W Z N, MADOW W G. Sample survey methods and theory[M]. New York:John wiley and Sons. Inc,1953.
[16] 蒋涛, 王永武. 免疫检测点抑制剂治疗非小细胞肺癌 [J]. 外科研究与新技术, 2014, 3(2): 145-148. JIANG Tao, WANG Yongwu. Immune checkpoint inhibitors for the treatment of non-small cell lung cancer [J]. Surgical Research and New Technique, 2014, 3(2): 145-148.
[17] 艾斌. 免疫检查点抑制剂在肿瘤治疗中的应用[J]. 医 学与哲学, 2015, 36(4): 18-21. AI Bin. The treatment of malignant tumor by immune checkpoint inhibitors[J]. Medicine & Philosophy, 2015, 36(4): 18-21.
[18] FRIDMAN W H, ZITVOGEL L, SAUT?S–FRIDMANV C, et al. The immune contexture in cancer prognosis and treatment[J]. Nature Reviews Clinical Oncology, 2017,14(12):717-734.
[19] FENG Mengyu, Xiong Guangbing, CAO Zhe, et al. PD-1/PD-L1 and immunotherapy for pancreatic cancer[J]. Cancer Letters, 2017, 407:57-65.
[20] 徐金良, 杜丹丹, 翟志敏, 等. 卵巢良恶性肿瘤患者血 液NLR,LMR,RDW,PLR 四项参数的变化及其临床意 义[J]. 现代检验医学杂志, 2018, 33(2): 16-18,22. XU Jinliang, DU Dandan, ZHAI Zhimin, et al.Changes and clinical significance of four parameters of NLR,LMR, RDW and PLR in patients with benign and malignant ovarian tumors[J]. Journal of Modern Laboratory Medicine, 2018, 33(2): 16-18.
[21] OTTENHOF S R, DJAJADININGRAT R S, THYGESEN H H, et al. The prognostic value of immune factors in the tumor microenvironment of penile squamous cell carcinoma [J]. Front Immunol, 2018,9:1253.
[22] SABATIER R, FINETTI P, MAMESSIER E, et al. Prognostic and predictive value of PDL1 expression in breast cancer [J]. Oncotarget, 2015, 6(7): 5449-5464.
[23] POSTOW M A, CALLAHAN M K, WOLCHOK J D. Immune checkpoint blockade in cancer therapy [J]. Journal of Clinical Oncology, 2015, 33(17): 1974-1982.
[24] 潘佳佳,贾晓青,黄岗, 等. PD-1/PD-Ls 信号通路 及其抗体在肿瘤治疗中的应用[J]. 中国药科大学学 报, 2016, 47(1): 9-18. PAN Jiajia, JIA Xiaoqing, HUANG Gang, et al. PD-1/ PD-Ls signal pathway and the application of anti-PD-1/ PD-Ls antibodies in cancer therapy[J]. Journal of China Pharmaceutical University, 2016, 47(1): 9-18.
[25] BULIAN P,SHANAFELT T D,FEGAN C, et al. CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia [J]. Journal of Clinical Oncology, 2014, 32(9): 897-904.
[26] CHINEN LTD, ABDALLAH E A, BRAUN A C, et al. circulating tumor cells as cancer biomarkers in the clinic[J]. Adv Exp Med Biol, 2017, 994:1-41.

相似文献/References:

[1]肖小平,郭 玲a,张 熊b.胆管癌组织LOXL2 mRNA与Tenascinm-C mRNA表达的临床应用研究[J].现代检验医学杂志,2017,32(03):79.[doi:10.3969/j.issn.1671-7414.2017.03.021]
 XIAO Xiao-ping,GUO Linga,ZHANG Xiongb.Clinical Application of the Expression of LOXL2 mRNA and Tenascin-C mRNA in Tissues of the Bile Duct Cancer[J].Journal of Modern Laboratory Medicine,2017,32(06):79.[doi:10.3969/j.issn.1671-7414.2017.03.021]
[2]王希方a,郑 伟b,马东瑞c,等.ALKBH5 调控GEFT 的m6A 修饰对胆管癌转移及EMT 的实验研究[J].现代检验医学杂志,2023,38(04):1.[doi:10.3969/j.issn.1671-7414.2023.04.001]
 WANG Xifanga,ZHENG Weib,MA Dongruic,et al.Experimental Study of GEFT m6A Modification Regulated by ALKBH5 on Cholangiocarcinoma Metastasis and EMT[J].Journal of Modern Laboratory Medicine,2023,38(06):1.[doi:10.3969/j.issn.1671-7414.2023.04.001]

备注/Memo

备注/Memo:
基金项目:陕西省自然科学基础研究计划项目(2012JQ4016)。 作者简介:遆振宇(1974 -),男,博士,副主任医师,研究方向:肝胆胰外科治疗,E-mail:xitizheny@163.com。 通讯作者: 高小鹏(1977 - ),男,博士,副主任医师,E-mail: gaoxiaopengmed@163.com。收稿日期:2019-08-20
更新日期/Last Update: 2019-12-25